Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 496 clinical trials
featured
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

advanced cancer
cancer
  • 128 views
  • 14 Dec, 2020
  • 4 locations
Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15% of all cases diagnosed correspond to the triple negative subtype. Triple negative breast cancer

  • 2 views
  • 23 Jan, 2021
  • 1 location
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.

  • 2 views
  • 07 Mar, 2021
  • 1 location
Immunopheresis Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Advanced Triple Negative Breast Cancer (TNBC)

Soluble Tumor Necrosis Factor Receptors (sTNF-Rs) from plasma of patients with advanced, refractory Triple Negative Breast Cancer (TNBC) and for disease control when employed as monotherapy, or in

  • 30 views
  • 27 Jan, 2021
  • 6 locations
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

hormone receptor-negative (HR-) (estrogen-receptor-negative (ER-) and progesterone-receptor-negative (PR-) human epidermal growth factor receptor 2 (HER2) negative/triple-negative breast cancer.

carboplatin
platelet count
progesterone receptor
thyroid-stimulating hormone
immunohistochemistry
  • 0 views
  • 22 Sep, 2021
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer

This is a multicenter single-arm phase II clinical trial to evaluate the efficacy and safety of olaparib in patients diagnosed of advanced triple negative breast cancer (TNBC) with methylation

tamoxifen
ct scan
serum pregnancy test
BRCA2
estrogen receptor
  • 18 views
  • 29 Jan, 2021
  • 25 locations
Functional Precision Oncology for Metastatic Breast Cancer

This is a pilot study to assess the feasibility of comprehensive genomic characterization and drug screening in metastatic breast cancer. The trial will seek to provide personalized genomic and drug sensitivity information to eligible patients with metastatic breast cancer prior to disease progression on standard treatment. The trial will also …

  • 0 views
  • 19 Apr, 2021
  • 1 location
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

This is a prospective, single center, randomized, open-labled stage III clinical trial comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast cancer.

triple negative breast cancer
carboplatin
paclitaxel
HER2
breast cancer
  • 20 views
  • 23 Jan, 2021
  • 1 location
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

patients with triple-negative breast cancer. Patients with stage II/III operable triple-negative breast cancer are eligible. Patients who need adjuvant chemotherapy after breast surgery as well as

anthracyclines
triple negative breast cancer
adjuvant therapy
sentinel node
adjuvant chemotherapy
  • 82 views
  • 23 Jan, 2021
  • 12 locations
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

metastatic triple negative breast cancer

antineoplastic
trastuzumab
triple negative breast cancer
paclitaxel
HER2
  • 400 views
  • 29 Aug, 2021
  • 65 locations